>

Novozymes Fundamental Trends Analysis

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>NO</div>
The Drivers Module shows relationships between Novozymes's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Novozymes B AS over time as well as its relative position and ranking within its peers. Check out Stocks Correlation.
View Current Fundamental Trends For
Refresh

Novozymes B AS Total Debt vs. Current Asset Fundamental Analysis

Novozymes B AS is considered to be number one stock in current asset category among related companies. It is rated top company in total debt category among related companies making up about  0.80  of Total Debt per Current Asset. The ratio of Current Asset to Total Debt for Novozymes B AS is roughly  1.26 
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Novozymes 
Current Asset 
 = 
Cash 
Deposits 
Liquid Assets 
=
6.25 B
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Novozymes 
Total Debt 
 = 
Bonds 
+  
Notes 
=
4.97 B
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Novozymes B AS is rated top company in total debt category among related companies. Total debt of Biotechnology industry is now estimated at about 5.06 Billion. Novozymes totals roughly 4.97 Billion in total debt claiming about 98% of stocks in Biotechnology industry.
Total debt  Workforce  Revenue  Capitalization  Valuation

Novozymes Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page